• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update - Product Image

PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update

  • Published: November 2012
  • Region: United States
  • 138 pages
  • GlobalData

PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update

Summary

GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

US physicians surveyed for this report state that they may follow guidelines such as ACR, but also follow their own clinical experience to treat patients. In the US, about 75% of patient referrals come from Primary Care Physicians (PCPs). Also, most patients who are referred present with signs and symptoms of moderate to severe RA. People seeking treatment are generally in the 55 and older age group. Within READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Treatment Overview
4.2 US
4.2.1 Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Enbrel (etanercept)
5.3.2 Humira (adalimumab)
5.3.3 Remicade (infliximab)
5.3.4 Simponi (golimumab)
5.3.5 Cimzia (certolizumab pegol)
5.3.6 Orencia (abatacept)
5.3.7 Actemra/RoActemra (tocilizumab)
5.3.8 Rituxan/MabThera (rituximab)
5.3.9 Methotrexate Sodium (numerous generic names)
5.3.10 DMARDs
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 More rheumatologists in the field and physician knowledge of the disease
6.2.2 More cost-effective therapies through oral formulation and biosimilars
6.2.3 The development of predictive tests and discovery of biomarkers
6.2.4 The discovery of curative therapies
6.2.5 Improved drug safety and efficacy profiles
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Predictive tools for diagnosis and treatment
6.4.2 Target specificity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Tofacitinib (CP-690550)
7.2.2 Tabalumab (LY2127399)
7.2.3 Fostamatinib (previously R788)
7.2.4 RAVAX
7.2.5 Secukinumab (AIN457)
7.2.6 Masitinib (AB101)
7.2.7 Baricitinib (formerly LY3009104/INCB28050)
7.2.8 Sarilumab (REGN88/SAR153191)
7.2.9 Sirukumab (CNTO 136)
8 Market Outlook
8.1 United States
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Abbreviations
9.2 Bibliography
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Rheumatoid Arthritis Patients
9.4.2 Percent Drug-treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analysts
9.7.2 Global Head of Healthcare
9.8 About Us
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis
Table 2: Treatment Guidelines for Rheumatoid Arthritis
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
Table 4: Treatment Guidelines for Rheumatoid Arthritis
Table 5: Product Profile - Enbrel
Table 6: 10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers
Table 7: 10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall
Table 8: Enbrel SWOT Analysis, 2012
Table 9: Product Profile - Humira
Table 10: Humira SWOT Analysis, 2012
Table 11: Product Profile - Remicade
Table 12: Remicade SWOT Analysis, 2012
Table 13: Product Profile - Simponi
Table 14: Simponi SWOT Analysis, 2012
Table 15: Product Profile - Cimzia
Table 16: Cimzia SWOT Analysis, 2012
Table 17: Product Profile - Orencia
Table 18: Orencia SWOT Analysis, 2012
Table 19: Product Profile - Actemra/RoActemra
Table 20: Actemra/RoActemra SWOT Analysis, 2012
Table 21: Product Profile - Rituxan
Table 22: Rituxan SWOT Analysis, 2012
Table 23: Product Profile - Methotrexate
Table 24: Methotrexate SWOT Analysis, 2012
Table 25: Summary of Minor Therapeutic Classes, 2012
Table 26: Overall Unmet Needs - Current Level of Attainment
Table 27: Clinical Unmet Needs - Gap Analysis, 2012
Table 28: Rheumatoid Arthritis - Phase Pipeline, 2012
Table 29: Comparison of Therapeutic Classes in Development for RA, 2012
Table 30: Product Profile - Tofacitinib
Table 31: Clinical Trial Locations by Country for Tofacitinib
Table 32: ORAL Standard ACR 20 Responses for Tofacitinib vs. Placebo vs. Humira at Month 6
Table 33: ORAL Step ACR 20, 50, 70 Responses for Tofacitinib vs. Placebo at Month Six
Table 34: Efficacy Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012
Table 35: Safety Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012
Table 36: Tofacitinib Clinical Trial Mortalities as of September 29, 2011
Table 37: Tofacitinib SWOT Analysis, 2012
Table 38: Product Profile - Tabalumab
Table 39: ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16
Table 40: Tabalumab SWOT Analysis, 2012
Table 41: Product Profile - Fostamatinib
Table 42: ACR Responses and DAS28 Scores for Fostamatinib vs. Placebo at Month Three
Table 43: Fostamatinib SWOT Analysis, 2012
Table 44: Product Profile - RAVAX
Table 45: RAVAX SWOT Analysis, 2012
Table 46: Product Profile - Secukinumab
Table 47: Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52
Table 48: Secukinumab SWOT Analysis, 2012
Table 49: Product Profile - Masitinib
Table 50: ACR Responses for Masitinib in the ITT Population (12 Weeks)
Table 51: ACR Responses for Masitinib in the ITT Population (12-82 Weeks)
Table 52: Masitinib SWOT Analysis, 2012
Table 53: Product Profile - Baricitinib
Table 54: ACR Responses for Baricitinib + MTX vs. Placebo + MTX at Week 12
Table 55: Safety of 4 and 8mg Baricitinib at Week 12
Table 56: Laboratory Values of 4 and 8mg Baricitinib at Week 12
Table 57: Baricitinib SWOT Analysis, 2012
Table 58: Product Profile - Sarilumab
Table 59: MOBILITY Study Results for Sarilumab at Week 12
Table 60: Sarilumab SWOT Analysis, 2012
Table 61: Product Profile - Sirukumab
Table 62: Sirukumab SWOT Analysis, 2012
Table 63: Sales Forecasts ($m) for Rheumatoid Arthritis in the United States
Table 64: Key Events Impacting Sales for Rheumatoid Arthritis in the United States, 2012
Table 65: Rheumatoid Arthritis Market - Drivers and Barriers in the United States, 2012
Table 66: Key Launch Dates
Table 67: Key Patent Expiries
Table 68: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
Figure 2: Rheumatoid Arthritis Biologic Drug Targets
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System
Figure 4: Severity of Rheumatoid Arthritis
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations-
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022
Figure 7: Sales for Rheumatoid Arthritis in the United States by Drug Class

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos